Bhalla Vikas sold 10,000 shares of ExlService Holdings, Inc (NASDAQ: EXLS). at $38.17 per share on September 1. Vikas, president of EXL, held 120,295 shares after the transaction.
Fabrinet (NYSE: FN) executive Edward T. Archer sold 2,500 shares across two transactions. The sales were completed at prices ranging from $385.58 to $386.34 per share.
Finance of America Companies Inc. (NYSE: FOA) President Sieffert Kristen N held 124,762 shares after selling part of her position. The transaction involved 750 shares at $17.55 per share.
Sloan Samantha L. executive vice president of corporate affairs at First Solar, held 2,353 First Solar shares after a transaction completed on September 1, 2026. The sequence included an option exercise, a share forfeiture and an exercise involving derivative securities.
Flutter Entertainment plc (NYSE: FLUT) Chief Financial Officer Coldrake Robert sold 710 shares in a transaction that left him holding 22,778 shares. The shares changed hands at $97.86 apiece, with the transaction completed on September 1, 2026.
EHealth, Inc. (NASDAQ: EHTH) awarded Chief Financial Officer Dolan John Joseph 70,000 shares at $0 per share. The transaction dated September 1, 2026, leaves Joseph with reported ownership of 343,275 eHealth shares.
Cunniff James L. forfeited 2,671 shares of Electromed, Inc (AMEX: ELMD). in an insider transaction dated September 1, 2026. The shares were valued at $27.10 each. Following the transaction, Cunniff owned 145,080 shares.
Entrada Therapeutics, Inc. (NASDAQ: TRDA) reported the forfeiture of 2,079 shares by Sethuraman Natarajan, its president of research and development. The transaction took place at $7.14 per share.
MPM BIOVENTURES 2018, L.P. sold 86,482 shares of Entrada Therapeutics, Inc (NASDAQ: TRDA). through separate transactions covering Sep 1 through Sep 3, 2026. The reported prices ranged from $7.06 to $7.19 per share, and the filing identifies MPM BIOVENTURES 2018, L.P. as an insider …
GADICKE ANSBERT’s insider transaction report records MPM BioVentures 2014, L.P. selling 86,482 shares of Entrada Therapeutics, Inc (NASDAQ: TRDA). The transactions involved an insider position and left the partnership with a disclosed ownership balance after the sales.